European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
 & Lead Plaintiff Deadline: April 14, 2017 - EconoTimes)
NEW YORK, March 10, 2017 -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Galena Biopharma, Inc. (“Galena” or the “Company”) (NASDAQ:GALE) and certain of its officers, and is on behalf of purchasers of Galena securities from August 11, 2014 through January 31, 2017, inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/gale.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Galena’s sales of Abstral were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) consequently, Galena’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/gale or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Galena you have until April 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
